Non-proteinuric diabetic kidney disease: State of art

  • J. Rico Fontalvo Asociación Colombiana de Nefrología, Comité de Nefrodiabetes, Bogotá Colombia
  • G. Aroca-Martínez Asociación Colombiana de Nefrología, Comité de Nefrodiabetes, Bogotá Colombia
  • R. Daza-Arnedo Servicio de Nefrología, Nuevo Hospital Bocagrande, Cartagena, Colombia
  • M. Raad-Sarabia Departamento de Medicina Interna, Facultad de Ciencias de la Salud, Universidad del Sinú, Cartagena, Colombia.
  • J. Luis Torres Servicio de Endocrinología, Clínica Las Américas Auna, Medellín Colombia
  • N. Pajaro-Galvis Departamento de Medicina Interna, Facultad de Ciencias de la Salud, Universidad del Sinú, Cartagena, Colombia
  • I. Uparella-Gulfo Departamento de Medicina, Facultad de Ciencias de la Salud, Universidad del Sinu, Cartagena, Colombia
  • D. Porto-Corbacho Departamento de Medicina Interna, Facultad de Ciencias de la Salud, Universidad del Sinú, Cartagena, Colombia.
  • S. Sarabia-Cannepa Unidad de Cuidados Intensivos Cardiovascular, Hospital Manuel Uribe Ángel, Medellín, Colombia
  • E. Ramos-Clason Departamento de Medicina, Facultad de Ciencias de la Salud, Universidad del Sinu, Cartagena, Colombia
Keywords: Diabetic kidney disease, non-albuminuric phenotype, albuminuric phenotype

Abstract

Diabetic kidney disease (DKD) is one of the chronic complications with the highest incidence of diabetes mellitus and is a public health problem today. Classically, five stages defined by Mogensen in 1980 have been described, where the presence of albuminuria stands out as an early marker of renal compromise. However, 20-30% of patients with DKD have been documented in recent years who do not present with proteinuria despite having a compromised glomerular filtration rate. This group has been called non-albuminuric phenotype ERD. Several atypical phenotypes have been described, the non-albuminuric phenotype being one of the most frequent in this group. Next, we review the non-albuminuric phenotype of diabetic kidney disease, from its pathophysiology to therapeutic measures that impact mortality and progression to end-stage kidney disease.

Published
2022-12-19
How to Cite
1.
Rico Fontalvo J, Aroca-Martínez G, Daza-Arnedo R, Raad-Sarabia M, Torres JL, Pajaro-Galvis N, Uparella-Gulfo I, Porto-Corbacho D, Sarabia-Cannepa S, Ramos-Clason E. Non-proteinuric diabetic kidney disease: State of art. Rev Nefrol Dial Traspl. [Internet]. 2022Dec.19 [cited 2024Dec.27];42(04):330-9. Available from: http://vps-1689312-x.dattaweb.com/index.php/rndt/article/view/860
Section
Review Article